GlassScriptPhysician profile
David Larson Demill
NPI 1366783631
$1,375.25
in general payments reported to CMS, 2019-2025
13 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $220 · 2021: $186 · 2022: $177 · 2023: $45.84 · 2024: $207 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $227.97 | 2025 | Photrexa Viscous and Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $163.45 | 2019-2021 | |
| Allergan, INC. | $150.00 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $148.42 | 2021 | |
| Bausch & Lomb Americas INC. | $146.35 | 2022-2024 | Envista Mx60 Iol, Miebo, Infuse |
| Dompe US, INC. | $124.96 | 2022 | |
| Aerie Pharmaceuticals, INC. | $117.01 | 2019 | |
| Alcon Vision LLC | $107.93 | 2023-2025 | Unity, Clareon, Centurion |
| Harrow Eye, LLC | $85.58 | 2024 | |
| New World Medical,INC. | $32.61 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $27.31 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $24.26 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Demill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.